Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.
Myachikova VY, Maslyanskiy AL, Moiseeva OM, Vinogradova OV, Gleykina EV, Lavrovsky Y, Abbate A, Grishin SA, Egorova AN, Schedrova ML, Samsonov MY. Myachikova VY, et al. Among authors: grishin sa. J Am Coll Cardiol. 2023 Jul 4;82(1):30-40. doi: 10.1016/j.jacc.2023.04.046. J Am Coll Cardiol. 2023. PMID: 37380301 Free article. Clinical Trial.
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.
Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, Samsonov M, Smolen JS, Fleischmann RM. Feist E, et al. Ann Rheum Dis. 2022 Dec;81(12):1661-1668. doi: 10.1136/ard-2022-222630. Epub 2022 Sep 15. Ann Rheum Dis. 2022. PMID: 36109142 Free PMC article. Clinical Trial.
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Feist E, Fleischmann RM, Fatenejad S, Bukhanova D, Grishin S, Kuzkina S, Luggen M, Nasonov E, Samsonov M, Smolen JS. Feist E, et al. Ann Rheum Dis. 2024 Oct 21;83(11):1454-1464. doi: 10.1136/ard-2023-225473. Ann Rheum Dis. 2024. PMID: 38955475 Free PMC article. Clinical Trial.
Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI).
Abbate A, Van Tassell B, Bogin V, Markley R, Pevzner DV, Cremer PC, Meray I, Privalov DV, Taylor A, Grishin SA, Egorova AN, Ponomar EG, Lavrovsky Y, Samsonov MY; RPH-104 STEMI Study Investigators. Abbate A, et al. Among authors: grishin sa. Circulation. 2024 Aug 13;150(7):580-582. doi: 10.1161/CIRCULATIONAHA.124.069396. Epub 2024 Aug 12. Circulation. 2024. PMID: 39133774 Clinical Trial. No abstract available.
Interleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment elevation myocardial infarction (STEMI): secondary endpoints from an international, double blind, randomized, placebo-controlled, phase IIa study.
Abbate A, Van Tassell B, Bogin V, Markley R, Pevzner DV, Cremer PC, Meray IA, Privalov DV, Taylor A, Grishin SA, Egorova AN, Ponomar EG, Lavrovsky Y, Samsonov MY. Abbate A, et al. Among authors: grishin sa. J Cardiovasc Pharmacol. 2024 Oct 2. doi: 10.1097/FJC.0000000000001635. Online ahead of print. J Cardiovasc Pharmacol. 2024. PMID: 39357146
Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.
Abbate A, Van Tassell B, Bogin V, Markley R, Pevzner DV, Cremer PC, Meray IA, Privalov DV, Taylor A, Grishin SA, Egorova AN, Ponomar EG, Lavrovsky Y, Samsonov MY. Abbate A, et al. Among authors: grishin sa. J Cardiovasc Pharmacol. 2024 Dec 1;84(6):565-577. doi: 10.1097/FJC.0000000000001635. J Cardiovasc Pharmacol. 2024. PMID: 39642282 Free PMC article. Clinical Trial.
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Smolen JS, et al. Among authors: grishin sa. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302. N Engl J Med. 2022. PMID: 36001712 Clinical Trial.
[Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)].
Neznamov GG, Siuniakov SA, Teleshova SE, Chumakov DV, Reutova MA, Siuniakov TS, Mametova LE, Dorofeeva OA, Grishin SA. Neznamov GG, et al. Among authors: grishin sa. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):20-6. Zh Nevrol Psikhiatr Im S S Korsakova. 2009. PMID: 19491814 Clinical Trial. Russian.
12 results